No Image 27Feb

by

Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

No Image 15Sep

by

Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

No Image 03Mar

by

Other news to note for March 2, 2021

No Image 03Mar

by

Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

No Image 01Jun

by

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

No Image 01Jun

by

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

No Image 01Jun

by

Yuhan to start phase-3 trial on lung cancer drug Lazertinib

No Image 01Jun

by

"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

No Image 01Jun

by

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

No Image 01Jun

by

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

No Image 01Jun

by

Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

No Image 01Jun

by

Oscotec wins exception policy for continued R&D for new drugs